Anixa Biosciences Inc 8K

Anixa Biosciences reported favorable survival and safety data from its Phase 1 ovarian cancer CAR‑T trial and received regulatory approval to significantly escalate dosing and add lymphodepletion under an amended protocol.

On February 9, 2026, Anixa Biosciences, Inc. announced encouraging patient survival data from its ongoing Phase 1 CAR‑T clinical trial in recurrent ovarian cancer and disclosed that, following regulatory and IRB approval of a protocol amendment obtained by its partner Moffitt Cancer Center, the trial will proceed with substantial dose escalation—up to 10^9 CAR‑positive cells/kg and potentially higher—while also introducing a lymphodepletion regimen (cyclophosphamide and fludarabine) in the next cohort to potentially enhance efficacy; the company reported that 7 of 12 treated patients have exceeded expected median survival with no dose‑limiting toxicities observed to date and noted that CEO Dr. Amit Kumar will discuss these developments in a Water Tower Research fireside chat on February 10, 2026.

Filing Facts

CIK

715446

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-005702

Alert Tier

6